10x Genomics Secures Landmark Patent Verdict Over Parse Biosciences' Infringement
In a landmark ruling delivered on August 28, 2026, 10x Genomics, Inc. (Nasdaq: TXG), a leading entity in life science technology, secured a vital patent infringement verdict against Parse Biosciences, a subsidiary of Qiagen (NYSE: QGEN). The U.S. District Court for Delaware concluded that Parse had willfully infringed upon three patents that are exclusively licensed to Scale Biosciences — a company that became part of 10x Genomics in the year 2025 — originating from cutting-edge innovations in single-cell analysis. These patents were licensed from Roche Sequencing Solutions.
The jury's decision was notable in that it not only affirmed the validity and enforceability of the patents but also dismissed Parse's attempts to challenge their legitimacy. Garry Nolan, PhD, one of the co-founders of Scale Biosciences, expressed immense pride in the advancements related to these patents, emphasizing that the ruling signifies the importance of original inventions in scientific progress.
"The jury's decision is an endorsement for inventors worldwide, highlighting that the original ideas matter and that robust patent protections are essential for facilitating scientific advancements," Dr. Nolan commented.
Giovanna Prout, the former CEO of Scale Biosciences, added that their commitment to nurturing high-quality technologies was vital in reshaping possibilities for researchers. She believes that safeguarding foundational intellectual property not only paves the way for future innovations but also guarantees respect and acknowledgment from others in the sector — something crucial for pioneering companies striving to further scientific discovery.
The jury awarded 10x Genomics more than $4.8 million in damages due to the infringing sales of Parse's Evercode Whole Transcriptome products, recorded from February 2021 until June 30, 2026. This amount was calculated based on a generous 14% royalty on Parse’s sales considered infringing. Furthermore, in subsequent legal proceedings, 10x intends to pursue additional compensations, which could involve enhanced damages and recovery of attorney's fees linked to Parse's deliberate patent infringement, alongside seeking a permanent injunction to prevent any future violations by Parse within the United States.
Randy Wu, General Counsel of 10x Genomics, remarked that the evidence established during the trial indicated a clear intention from Parse to disregard Dr. Nolan’s foundational inventions in single-cell analysis. The jury heard the presented evidence and decisively dismissed Parse's defenses, ruling that there was willful infringement on the part of Parse concerning the patents linked with Scale.
The patents in question are U.S. Patent Nos. 10,626,442, 10,982,256, and 11,512,341, and their significance stretches beyond the current case, impacting how scientists and researchers can approach biological analysis in the future.
10x Genomics continues to forge ahead with innovations designed to advance human health and biological understanding. Their suite of integrated research solutions—including specialized instruments, consumables, and software—works hand-in-hand with academic and biopharmaceutical researchers, elucidating complex biological systems at unprecedented resolutions.
In light of this ruling, it’s clear that 10x Genomics is not only committed to their scientific endeavors but also to safeguarding the innovation necessary for future advancements. This case sets a precedent that reinforces the importance of patent rights and is a decisive win for the biotech industry’s landscape.
The jury's decision was notable in that it not only affirmed the validity and enforceability of the patents but also dismissed Parse's attempts to challenge their legitimacy. Garry Nolan, PhD, one of the co-founders of Scale Biosciences, expressed immense pride in the advancements related to these patents, emphasizing that the ruling signifies the importance of original inventions in scientific progress.
"The jury's decision is an endorsement for inventors worldwide, highlighting that the original ideas matter and that robust patent protections are essential for facilitating scientific advancements," Dr. Nolan commented.
Giovanna Prout, the former CEO of Scale Biosciences, added that their commitment to nurturing high-quality technologies was vital in reshaping possibilities for researchers. She believes that safeguarding foundational intellectual property not only paves the way for future innovations but also guarantees respect and acknowledgment from others in the sector — something crucial for pioneering companies striving to further scientific discovery.
The jury awarded 10x Genomics more than $4.8 million in damages due to the infringing sales of Parse's Evercode Whole Transcriptome products, recorded from February 2021 until June 30, 2026. This amount was calculated based on a generous 14% royalty on Parse’s sales considered infringing. Furthermore, in subsequent legal proceedings, 10x intends to pursue additional compensations, which could involve enhanced damages and recovery of attorney's fees linked to Parse's deliberate patent infringement, alongside seeking a permanent injunction to prevent any future violations by Parse within the United States.
Randy Wu, General Counsel of 10x Genomics, remarked that the evidence established during the trial indicated a clear intention from Parse to disregard Dr. Nolan’s foundational inventions in single-cell analysis. The jury heard the presented evidence and decisively dismissed Parse's defenses, ruling that there was willful infringement on the part of Parse concerning the patents linked with Scale.
The patents in question are U.S. Patent Nos. 10,626,442, 10,982,256, and 11,512,341, and their significance stretches beyond the current case, impacting how scientists and researchers can approach biological analysis in the future.
10x Genomics continues to forge ahead with innovations designed to advance human health and biological understanding. Their suite of integrated research solutions—including specialized instruments, consumables, and software—works hand-in-hand with academic and biopharmaceutical researchers, elucidating complex biological systems at unprecedented resolutions.
In light of this ruling, it’s clear that 10x Genomics is not only committed to their scientific endeavors but also to safeguarding the innovation necessary for future advancements. This case sets a precedent that reinforces the importance of patent rights and is a decisive win for the biotech industry’s landscape.
Topics Other）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.